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The cytokine transforming growth factor β (TGFβ) plays a crucial role in the induction of 
both epithelial-to-mesenchymal transition (EMT) program and fibro-cirrhotic process in the 
liver, where it contributes also to organ inflammation following several chronic injuries. All 
these pathological situations greatly increase the risk of hepatocellular carcinoma (HCC) 
and contribute to tumor progression. In particular, late-stage HCCs are characterized by 
constitutive activation of TGFβ pathway and by an EMT molecular signature leading to 
the acquisition of invasive and metastatic properties. In these pathological conditions, the 
cytokine has been shown to induce the transcriptional downregulation of HNF1α, a master 
regulator of the epithelial/hepatocyte differentiation and of the EMT reverse process, 
the mesenchymal-to-epithelial transition (MET). Therefore, the restoration of HNF1α 
expression/activity has been proposed as targeted therapeutic strategy for liver fibro-
cirrhosis and late-stage HCCs. In this study, TGFβ is found to trigger an early functional 
inactivation of HNF1α during EMT process that anticipates the effects of the transcriptional 
downregulation of its own gene. Mechanistically, the cytokine, while not affecting the 
HNF1α DNA-binding capacity, impaired its ability to recruit CBP/p300 acetyltransferases 
on target gene promoters and, consequently, its transactivating function. The loss of 
HNF1α capacity to bind to CBP/p300 and HNF1α functional inactivation have been found 
to correlate with a change of its posttranslational modification profile. Collectively, the 
results obtained in this work unveil a new level of HNF1α functional inactivation by TGFβ 
and contribute to shed light on the early events triggering EMT in hepatocytes. Moreover, 
these data suggest that the use of HNF1α as anti-EMT tool in a TGFβ-containing 
microenvironment may require the design of new therapeutic strategies overcoming the 
TGFβ-induced HNF1α inactivation.
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INTRODUCTION
Transforming growth factor β (TGFβ) has emerged as a major 
microenvironmental factor playing a role in all phases of 
chronic liver diseases (Fabregat et al., 2016). This cytokine, in 
fact, is primarily involved in liver inflammation (by stimulating 
lymphocytes to produce inflammatory cytokines), in fibrosis 
(by activating the trans-differentiation of hepatic stellate cells to 
myofibroblasts and the subsequent production of large amount 
of extracellular matrix), and in the onset of hepatocellular 
carcinoma (HCC) that, in almost all the cases, develops on 
the described pathological tissue background (Amicone and 
Marchetti, 2018). Furthermore, once the tumor is established, the 
continuous production of TGFβ by both tumor and nontumor 
tissue, contributes to its growth and metastasization, mainly 
through the induction of epithelial-to-mesenchymal transition 
(EMT) in transformed hepatocytes (Zavadil and Bottinger, 
2005). Accordingly, an unbalanced level of the cytokine in the 
tumor niche and high amount of the circulating cytokine have 
been shown to contribute to tumor progression and to a poor 
prognosis (Amicone et al., 2002; Lee et al., 2012).
TGFβ is a well-known inducer of EMT in several types of 
epithelial cells. In hepatocytes, the cytokine induces the trans-
differentiation process through the upregulation of EMT/
mesenchymal genes (Xu et al., 2009) and the strong transcriptional 
downregulation of master regulators of epithelial/hepatocyte 
differentiation, such as HNF4α and HNF1α (Marchetti et al., 2013).
In particular, TGFβ was shown to interfere with HNF4α and 
HNF1α gene expression in hepatocytes by upregulating the 
EMT master gene Snail, a transcriptional inhibitor that, in turn, 
induces HNF4α and HNF1α transcriptional repression through 
the direct binding to their promoters (Cicchini et al., 2006; 
Cozzolino et al., 2013; Battistelli et al., 2017).
HNF4α and HNF1α are well-known master regulators of 
hepatocyte differentiation, able to drive a complex epithelial/
hepatocyte transcriptional program. Recently, it has been shown 
that, in fully differentiated hepatocytes, HNF4α and HNF1α 
are responsible not only for the maintenance of the epithelial 
program but also for a stable and continuous inhibition of the 
mesenchymal one, through the transcriptional repression of 
EMT/mesenchymal genes (Noce et al., in press; Santangelo et al., 
2011). Furthermore, these proteins have been largely described 
as mesenchymal-to-epithelial transition (MET) master genes 
and tumor suppressors. HNF4α and HNF1α expression is lost 
during liver fibrosis and HCC progression (Lazarevich et  al., 
2004; Lazarevich et al., 2010; Willson et al., 2013; Ni et al., 2017), 
while their exogenous expression triggers growth arrest in 
hepatoma cell lines (Lazarevich et al., 2004; Pelletier et al., 2011) 
and induces hepatocyte differentiation in dedifferentiated cells 
(Santangelo et al., 2011). Most significantly, HNF4α and HNF1α 
delivery in animal models attenuates liver fibrosis (Yue et al., 
2010; Song et al., 2016) and inhibits growth of xenograft tumors 
(Ning et al., 2010; Zeng et al., 2011).
For all these reasons, HNF4α and HNF1α have been proposed 
as therapeutic molecules for HCC (Marchetti et al., 2015).
However, recent data from our laboratory suggested that, in 
a TGFβ-containing environment, such as that in which HCC 
develops, the restoration of HNF4α function is not effective 
in suppressing the malignant behavior. We unveiled, in fact, 
a functional inactivation of HNF4α by TGFβ due to specific 
posttranslational modifications (PTMs) on the protein that 
correlate with the early loss of target gene promoters binding 
capacity (Cozzolino et al., 2013).
Here, we show that also HNF1α is subjected to a further level 
of TGFβ-induced downregulation, other than the transcriptional 
one. While TGFβ does not interfere with the HNF1α ability to 
bind to DNA, it negatively impairs HNF1α activity affecting its 
capacity to interact with CBP/p300 histone acetyltransferases. 
The loss of CBP/p300 recruitment on regulatory regions 
of HNF1α target genes, with consequent loss of a main 
transcription activating chromatin modification, prevents the 
HNF1α transcriptional function. Furthermore, we correlated 
the functional inactivation of HNF1α protein to a change in its 
PTM profile.
Altogether, our results demonstrate a new level of control of 
HNF1α by TGFβ that can represent the first event in triggering 
EMT process in hepatocyte and disclose a potential limitation 
to the use of an exogenous molecule as therapeutic MET 
inducer and tumor suppressor tool. However, and notably, the 
described mechanisms could allow the design of new therapeutic 
approaches aimed at overcoming the inactivating effect 
of the cytokine.
MATERIALS AND METHODS
Cell Cultures and Treatments
Nontumorigenic murine hepatocytes (Amicone et al., 1997) 
and their Ras-transformed counterpart (Cozzolino et al., 2013) 
were grown on collagen-I-coated dishes in RPMI-1640 medium 
supplemented with 10% fetal bovine serum (GIBCO® Life 
Technology, Monza, Italy), 50  ng/ml epidermal growth factor, 
30  ng/ml insulin-like growth factor II (PeproTech Inc., Rocky 
Hill, NJ, USA), 10  µg/ml insulin (Roche, Mannheim, Germany), 
and antibiotics. Where indicated, cells were treated with 4 ng/ml 
of TGFβ1 (PeproTech Inc., Rocky Hill, NJ, USA) for the indicated 
time. As previously reported, cell lines utilized in this study undergo 
EMT following TGFβ treatment (Cozzolino et al., 2013; Grassi 
et al., 2015; De Santis Puzzonia et al., 2016; Battistelli et al., 2018).
HNF1α-overexpressing cells were obtained by transient 
transfection with pLPCX-HNF1αMyc (carrying the rat HNF1α 
cDNA, Myc-tagged at the 5’ end). Control cell lines were obtained 
by transfection with the empty vector. Nontumorigenic and Ras-
transformed hepatocytes were transfected with Lipofectamine 
2000 (Invitrogen, San Diego, CA) or FuGENE® HD Transfection 
Reagent (Promega Corporation, Madison, WI), respectively, 
according to the manufacturer’s protocol, and collected 48  h 
after transfection.
RNA Extraction, Reverse Transcription, 
and Quantitative Real-Time PCR
Total RNAs were extracted with Total RNA Mini Kit (Geneaid) 
according to manufacturer’s protocol and reverse-transcribed 
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using PrimeScript RT Master Mix (Takara, Dalian, China). 
cDNA was amplified by qPCR using GoTaq qPCR Master Mix 
(Promega Corporation, Madison, WI) in BioRad-iQ-iCycler. 
Relative amounts, calculated with the 2(−ΔCt) method, were 
normalized with respect to the housekeeping gene RPL34 (60S 
ribosomal protein L34) or 18S rRNA. The sequence of primers 
utilized are listed in Table 1.
SDS-PAGE and Western Blotting
Cells were lysed in radioimmunoprecipitation assay buffer 
containing freshly added cocktail protease inhibitors [complete, 
ethylenediaminetetraacetic acid (EDTA)-free protease inhibitor 
cocktail; Sigma-Aldrich, St. Louis, MO]. Western Blots were 
performed as previously described (Cozzolino et al., 2013) using 
the following primary antibodies: rabbit polyclonal α-HNF1α 
(NBP1-33596, 1:1000; Novus Biologicals, USA), rabbit polyclonal 
α-CBP/p300 (451, 1:1000; Santa Cruz Biotechnology Inc., Santa 
Cruz, CA, USA), rabbit monoclonal α-cyclin-dependent kinase 4 
(CD22, 1:1000; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA), and mouse monoclonal α-glyceraldehyde 3-phosphate 
dehydrogenase (MAB374, 1:1000; Millipore Corp., Bedford, MA, 
USA). Blots were then incubated with horseradish-peroxidase-
conjugated species-specific secondary antibodies (Bio-Rad, 
Hercules, CA, USA), followed by enhanced chemiluminescence 
reaction (Bio-Rad Laboratories Inc., Hercules, CA, USA). 
Densitometric analyses were performed with ImageJ.
Immunofluorescence Staining
For indirect immunofluorescence analysis, cells were fixed in 
4% paraformaldehyde, permeabilized with 0.2% Triton-X100, 
and incubated with α-HNF1α antibody (NBP1-33596, 
1:50; Novus Biologicals, USA), α-Myc-Tag antibody (9B11, 
1:200; Cell Signaling Technologies Inc. Danvers, USA), and 
E-cadherin antibody (610182, 1:50; BD Biosciences). Alexa 
Fluor 488-conjugated and Alexa Fluor-594-conjugated 
secondary antibodies (1:400; Molecular Probes, Eugene, OR, 
USA) were utilized. Nuclei were stained with 4’,6-diamidino-2-
phenylindole (DAPI; Calbiochem Merck, Darmstadt, Germany). 
Images were examined with a Nikon Eclipse microscope (Nikon 
Corporation, Tokyo, Japan) equipped with a charge-coupled 
device camera. Digital images were acquired by Nikon NIS 
elements software (Nikon Corporation, Tokyo, Japan) and 
processed with Adobe Photoshop 7 software (Adobe Systems, 
Mountain View, CA). The same enhanced color levels were 
applied for all channels.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) analysis was performed 
as previously reported (Cozzolino et al., 2016; Battistelli 
et al., 2017) using 5  μg of the following antibodies for the 
immunoprecipitation: goat polyclonal α-HNF1α (C-19; Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA), rabbit polyclonal 
α-CBP (451; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA), rabbit polyclonal α-acetyl H3 (06-599; Millipore Corp., 
Bedford, MA, USA), normal rabbit antiserum (Millipore Corp., 
Bedford, MA, USA), and normal goat IgG (AB-108-C; R&D 
Systems, Minneapolis, USA) were used as negative controls. 
Equal amounts of immunoprecipitated DNA and relative controls 
were used for qPCR analysis, performed in triplicate. The list 
of primers utilized is shown in Table 2. qPCR analysis of the 
immunoprecipitated samples and of the negative controls (IgG) 
were both normalized to total chromatin input. The promoter of 
Neurogenin 1, a gene not expressed in hepatocytes, was used as 
negative control.
Electrophoretic Mobility Shift Assay
Cells were scraped in cold phosphate-buffered saline (PBS), lysed 
in 10 mM Hepes pH 7.9, 1.5 mM MgCl2, 10 mM KCl, 0.1% NP40, 
0.1 mM EDTA, 0.5 mM dithiothreitol (DTT), standard protease 
and phosphatase inhibitors, and centrifuged to pellet the nuclei. 
Nuclear proteins were extracted in 20 mM Hepes pH 7.9, 20% 
glycerol, 0.42  M NaCl, 1.5  mM MgCl2, 0.2  mM EDTA, 0.1% 
TABLE 1 | List of mouse primers used for RT-qPCR experiments.
Gene Forward primer Reverse primer
HNF4α 5’-TCTTCTTTGATCCAGATGCC-3’ 5’-GGTCGTTGATGTAATCCTCC-3’
HNF1α 5’-TATCATGGCCTCGCTACCTG-3’ 5’ -ACTCCCCATGCTGTTGATGA-3’
TTR 5’-CCATGAATTCGCGGATGTGG-3’ 5’-TCAATTCTGGGGGTTGCTGA-3’
Albumin 5’-TTCCTGGGCACGTTCTTGTA-3’ 5’-GCAGCACTTTTCCAGAGTGG-3’
18S 5’-ACGACCCATTCGAACGTCTG-3’ 5’ -GCACGGCGACTACCATCG-3’
RPL34 5’-GGAGCCCCATCCAGACTC-3’ 5’ -CGCTGGATATGGCTTTCCTA -3’
TABLE 2 | List of mouse primers used for qPCR in ChIP experiments.
Promoter Forward primer Reverse primer
Albumin 5’-AGGAACCAATGAAATGCGAGG-3’ 5’-AGACGAAGAGGAGGAGGAGA-3’
HNF4α 5’-ACTTGGGCTCCATAGCAAGA-3’ 5’- CAGGACAGGCACAGACAAGA-3’
Neurog1 5’-CCTCCCGCGAGCATAAATTA-3’ 5’-GCGATCAGATCAGCTCCTGT -3’
RPL30 5’-TAAGGCAGGAAGATGGTGG -3’ 5’- CAGTGTGCTCAAATCTATCC-3’
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NP40, 0.5  mM DTT, and standard protease inhibitors. Protein 
concentrations were determined with the Bio-Rad Protein Assay 
Dye Reagent (Bio-Rad Laboratories, Hercules, CA).
For nonradioactive electrophoretic mobility shift assay (EMSA), 
biotin end-labeled oligonucleotide probes were obtained with the 
Biotin 3′ End DNA Labeling Kit (Thermo Fisher Scientific, Waltham, 
MA, USA), according to manufacturer’s protocol. The sequences 
of oligonucleotides used are the followings: for the mouse HNF4α 
promoter, 5’-CGGGGTGATTAACCATTAACTCCTACCCCT-3’ 
and 5’-AGGGGTAGGAGTTAATGGTTAATCACCCCG-3’ 
(the HNF1α binding site is underlined); for the mouse ApoC3 
promoter, 5’-CAGCAGGTGACCTTTGCCCAGCTCAC-3’ and 
5’-GTGAGCTGGGCAAAGGTCACCTGCTG-3’ (the HNF4α 
binding site is underlined).
Gel shift assays were performed using LightShift 
Chemiluminescent EMSA Kit (Thermo Fisher Scientific, 
Waltham, MA, USA), according to the manufacturer’s protocol. 
The binding reaction was prepared in a final volume of 20  µl 
incubating 1× binding buffer, 2.5% glycerol, 5  mM MgCl2, 
50 ng/µl PolydI-dC, 0.05% NP-40, and 10 µg of nuclear extracts 
(except for the free probe sample) for 10’ at 4°C. Then, 25 fmol 
of the double-strand biotinylated probe were added and the 
reaction conducted for further 20’ at RT. Where specified, 
a 100-fold excess of unlabeled annealed oligonucleotide or 
5  µg of the following antibodies were added to the binding 
reaction before addition of nuclear extracts: rabbit polyclonal 
α-HNF1α (H-140; Santa Cruz Biotechnology Inc., Santa Cruz, 
CA, USA) or rabbit polyclonal α-HNF1α (NBP1-33596; Novus 
Biologicals) and mouse monoclonal α-tubulin (TU-02; Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA). Samples were 
loaded on a 6% nondenaturing polyacrylamide gel in 0.5× tris 
borate EDTA and transferred to a nylon membrane (Biodyne 
B Nylon Membrane, Thermo Fisher Scientific, Waltham, MA, 
USA). After cross-linking to the membrane at 120  mJ/cm2 for 
1’ with UV Stratalinker 1800 (Stratagene, San Diego, CA, USA), 
biotin-labeled DNA was detected using Chemiluminescent 
Nucleic Acid Detection Module Kit (Thermo Fisher Scientific, 
Waltham, MA, USA).
Co-immunoprecipitation
Cells were lysed in IP lysis buffer (150 mM NaCl, 50 mM Tris–
HCl pH  7.5, 2  mM EDTA, 1% Triton-X100, 10% glycerol) 
supplemented with protease and phosphatase inhibitors. 
One milligram of cell lysates, after preclearing with protein 
A-Sepharose (GE Healthcare, Little Chalfont, Buckinghamshire, 
UK), was incubated with 5  µg of goat polyclonal α-HNF1α 
antibody (C-19; Santa Cruz Biotechnology Inc., Santa Cruz, CA, 
USA) or normal goat immunoglobulin G (IgG) (AB-108-C; R&D 
Systems, Minneapolis, USA) at 4°C overnight while rotating. 
Immunocomplexes were then incubated on a rotating platform 
for 3  h with protein A-sepharose at 4°C, washed in NetGel 
buffer (150 mM NaCl; 50 mM Tris–HCl pH 7.5; 1 mM EDTA; 
0.1% NP-40; 0.25% gelatin), eluted and denatured in Laemmli 
buffer. Proteins from immunoprecipitation were resolved on 
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred to nitrocellulose membrane 
(Bio-Rad Laboratories, Hercules, CA). For immunoblotting, 
the following primary antibodies were used: rabbit polyclonal 
α-HNF1α (NBP1-33596, 1:2000; Novus Biologicals) and rabbit 
polyclonal α-CBP (451, 1:1000; Santa Cruz Biotechnology, Santa 
Cruz, CA). Immune complexes were detected with horseradish 
peroxidase-conjugated species-specific secondary antiserum 
(Bio-Rad Laboratories, Hercules, CA), followed by enhanced 
chemiluminescence reaction (Bio-Rad Laboratories Inc., 
Hercules, CA, USA).
Two-Dimensional Gel Electrophoresis
Two-dimensional gel electrophoresis (2-DE) was performed 
using IPGphor II (GE Healthcare) as previously described 
(Cozzolino et al., 2013). In brief, proteins (90 µg) from nuclear 
extracts were precipitated with 100% acetone and then loaded 
on pH 3–10 IPG strips (IPGs) and electrofocused at 15,000 V/h 
at a maximum voltage of 5,000  V. The second-dimension 
separation was performed at a constant current of 50 mA for 2 h. 
Proteins were transferred to nitrocellulose membranes (Protran 
Nitrocellulose Transfer Membrane, Schleicher & Schuell, BD 
Biosciences), and Western blot was performed as described 
above with mouse monoclonal anti-Myc-Tag antibody (9B11, 
1:1,000; Cell Signaling Technologies Inc. Danvers, USA).
Statistical Analysis
Statistical significance was determined using paired one-
tailed Student’s t-test or one-sample Student’s t-test. A p < 0.05 
was considered statistically significant (*p < 0.05; **p < 0.01; 
***p < 0.001).
RESULTS
TGFβ Early Impairs HNF1α Functional 
Activity
It has previously reported that TGFβ is able to interfere with the 
activity of the hepatocyte differentiation master gene HNF4α, 
negatively controlling both gene expression and protein function 
(Santangelo et al., 2011; Cozzolino et al., 2013; Battistelli et al., 
2017). These findings had seriously questioned the possibility 
of using HNF4α as therapeutic molecule. In order to verify 
the possibility to use alternatively HNF1α as MET inducer in 
a TGFβ-rich microenvironment, we explored the effect of this 
cytokine on the HNF1α protein function.
To this aim, we utilized liver cell lines, already described in 
our laboratory, as models of hepatocytes at different stages of 
differentiation (Amicone et al., 1997; Bellovino et al., 1998; 
Grassi et al., 2015) and able to undergo EMT upon TGFβ 
treatment (Grassi et al., 2015; De Santis Puzzonia et al., 2016). 
The first evidence of an additional level of HNF1α negative 
control induced by TGFβ came from a time course analysis of 
HNF1α-dependent gene expression regulation in hepatocytes 
treated with the cytokine.
Figure 1A shows that, as expected, TGFβ induced a significant 
and early transcriptional downregulation of HNF1α (at 3  h of 
treatment) and of its target genes HNF4α (at 6 h of treatment), 
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Albumin and Transthyretin (TTR) (at 3  h of treatment). 
Notably, the downregulation of the target genes occurred when 
the reduction in the HNF1α protein was not yet observable 
(Figure 1B), thus suggesting a functional inactivation of HNF1α 
protein by TGFβ that precedes the effects of the transcriptional 
downregulation of its own gene.
To formally prove the posttranslational control of HNF1α by 
TGFβ, we constitutively expressed an exogenous HNF1α in a not 
fully differentiated hepatocyte cell line and in Ras-transformed 
hepatocytes (Cozzolino et al., 2013).
HNF1α target gene expression (Albumin and TTR), markedly 
induced by the exogenous HNF1α, was significantly reduced 
by TGFβ in both cell lines (Figure 2A and Supplementary 
Figure S1A), while the ectopic HNF1α protein level 
(Supplementary Figure S1B) and its nuclear localization 
(Figure 2B) were not modified. Furthermore, exogenous 
HNF1α was not able to hamper the TGFβ-induced EMT, 
as indicated by the transcriptional upregulation of Snail 
(Figure 2C), the downregulation and delocalization of E-cadherin 
(Figures 2C, D), and by the morphological transition (Figure 2B).
These data unveiled the dominance of TGFβ on HNF1α 
overexpression, both in the regulation of target gene expression 
and in the induction of EMT, thus confirming its ability to 
negatively control HNF1α at posttranscriptional level.
TGFβ Does Not Affect DNA Binding 
Capacity of HNF1α
In an attempt to investigate the mechanisms involved in TGFβ-
dependent HNF1α inactivation, HNF1α binding to regulatory 
sequences of its target genes HNF4α and Albumin has been 
evaluated by a chromatin immunoprecipitation (ChIP) assay, 
at early time of TGFβ treatment. As shown in Figure 3A, the 
HNF1α DNA binding activity was not affected by TGFβ even 
FIGURE 1 | Analysis of HNF1α transcriptional activity in hepatocytes following transforming growth factor β (TGFβ) treatment. (A) Gene expression analysis by 
RT-qPCR of HNF1α and the indicated target genes in hepatocytes in a time-course experiment following TGFβ treatment. qPCR data, obtained in triplicate and 
normalized to the ribosomal RNA 18S, are expressed as fold change in gene expression in TGFβ-treated versus untreated cells (arbitrary value = 1) (#p <0.06). 
The mean ± SEM of three independent experiments is shown. The observed differences in gene expression are statistically significant (*p < 0.05; **p < 0.01; ***p < 
0.001). (B) Western blot analysis for HNF1α in protein extracts from one of the experiments shown in (A). α-Glyceraldehyde 3-phosphate dehydrogenase was used 
as loading control. Densitometric analysis of WB data from three independent experiments is shown.
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after 5 h of treatment. Later time points were not analyzed since 
endogenous HNF1α was transcriptionally downregulated upon 
TGFβ treatment, as reported above.
However, and coherently with transcriptional data, the 
chromatin regions around the HNF1α binding site showed, 
at early time points after TGFβ treatment, a significant 
downregulation of the histone H3 acetylation, one of the 
main transcriptional activating chromatin modifications 
(Figure 3B).
Further evidence of the maintenance of HNF1α binding 
capacity in TGFβ-treated cells have been obtained by EMSA 
experiments. As shown in Figure 3C, the HNF1α/DNA complexes 
FIGURE 2 | TGFβ overrides HNF1α constitutive expression. (A) Analysis of constitutively expressed HNF1α activity following TGFβ treatment. RT-qPCR analysis for the 
indicated genes in hepatocytes, transiently transfected with pLCPX-HNF1αMyc (HNF1) or the empty vector (CTR), treated with 4 ng/ml TGFβ for 24 h or left untreated 
(NT). qPCR data, obtained in triplicate and normalized to the housekeeping gene RPL34, are expressed as relative gene expression. The mean ± SEM of three 
independent experiments is shown. Statistically significant differences are reported (*p < 0.05; ns, not significant). (B) Immunofluorescence analysis of hepatocytes 
transfected and treated as in (A). Cells were stained with anti-MycTag antibody (red) and 4’,6-diamidino-2-phenylindole (nuclei, blue). Magnification 10×. (C) Analysis 
of EMT-related gene expression by RT-qPCR in hepatocytes, transiently transfected with pLCPX-HNF1αMyc (HNF1) or the empty vector (CTR), treated with TGFβ for 
24 h or left untreated (NT). qPCR data, obtained in triplicate and normalized to the housekeeping gene RPL34, are expressed as relative gene expression. The mean 
± SEM of three independent experiments is shown. Statistically significant differences are reported (*p < 0.05; ns, not significant). (D) Immunofluorescence analysis of 
hepatocytes transfected and treated as in (C). Cells were stained with anti-E-cadherin (green) or anti-HNF1α antibody (red). Magnification 20×.
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were observed and maintained until 5 h of TGFβ treatment (when 
the endogenous protein is still expressed, as shown in Figure 1B) 
in untreated parental hepatocytes and until 24 h of treatment in 
hepatocytes constitutively expressing HNF1α, thus confirming 
that the mechanism involved in the HNF1α inactivation does 
not impact on its DNA binding ability. On the contrary, and as 
expected, in the same extracts, the binding of endogenous HNF4α 
on its own consensus site within the promoter of ApoC3 gene, 
was lost at early time points (5 h) of TGFβ treatment (Figure 3C, 
lower panel).
Overall, these data showed that TGFβ-induced functional 
inactivation of HNF1α does not depend on the loss of its DNA 
FIGURE 3 | (A) HNF1α DNA binding activity after TGFβ treatment. qPCR analysis of chromatin immunoprecipitated from hepatocytes with anti-HNF1α antibody 
was performed. HNF1α consensus regions embedded in the indicated HNF1α target gene promoters were analyzed. A HNF1α nonbound region of Neurogenin 1 
promoter was utilized as negative control. Data are normalized to total chromatin input and background (control immunoprecipitation with IgG) and expressed 
as % input. Mean ± SEM of qPCR data obtained in triplicate from three independent experiments are reported. (B) Analysis of acetyl histone H3 by chromatin 
immunoprecipitation assay in untreated and TGFβ-treated hepatocytes. qPCR analysis of chromatin immunoprecipitated from hepatocytes with anti-acetyl H3 
antibody was performed. HNF1α consensus regions embedded in the indicated HNF1α target gene promoters were analyzed. A HNF1α nonbound region of 
Neurogenin 1 promoter was utilized as negative control. Data are normalized to total chromatin input and background (control immunoprecipitation with IgG) 
and expressed as (Ip/IgG) % input. The mean ± SEM of qPCR data obtained in triplicate from five independent experiments are reported. *p <0.05, **p <0.01. 
(C) Electrophoretic mobility shift assay (EMSA) assays. Nuclear extracts from untreated (NT) or TGFβ-treated (for 5 or 24 h) parental (left, upper panel) or HNF1α-
overexpressing hepatocytes (right, upper panel) were analyzed for the binding to HNF1α consensus site within the murine HNF4α promoter. The presence of the 
HNF1α protein in the protein/DNA complexes was revealed by the band supershift obtained with the addition of two different anti-HNF1α antibodies. A 200-fold 
excess of unlabeled oligonucleotide and the antitubulin antibody were added to the untreated extracts to test the binding specificity. As control, HNF4α DNA binding 
activity to its consensus site within the ApoC3 promoter was analyzed by EMSA in the same extracts (lower panel).
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binding, but rather to the impairment of its ability to drive 
transcription activating chromatin modifications.
TGFβ Induces HNF1α Functional 
Inactivation Interfering With 
the Recruitment of CBP/p300 
Acetyltransferases
The correlation between the TGFβ-induced HNF1α functional 
inactivation and the loss of histone acetylation at its specific 
binding sites prompted us to investigate on the possible 
interference of TGFβ with the recruitment of histone 
acetyltransferase on the HNF1α target gene promoters. It has 
been previously shown that HNF1α interacts with the histone 
acetyltransferases CBP/p300 on target gene promoters (Ban 
et al., 2002; Dohda et al., 2004) and that the HNF1α-dependent 
nucleosome hyperacetylation is required for the activation of 
tissue-specific target genes (Parrizas et al., 2001). Thus, we 
analyzed by ChIP the effects of the TGFβ treatment on the 
CBP/p300 occupancy of HNF1α binding sites embedded in 
Albumin and HNF4α gene promoters. Our results demonstrated 
the presence of CBP/p300 in the untreated sample and, 
interestingly, the early displacement of these proteins upon 
TGFβ treatment (Figure 4A).
To investigate on the mechanism involved in the lack 
of histone acetyltransferase recruitment on DNA, the 
physical interaction between CBP/p300 and HNF1α has 
been evaluated in a coimmunoprecipitation assay, in the 
absence or in the presence of TGFβ (at 5 h of treatment). As 
shown in Figure 4B, the antibody specifically recognizing 
HNF1α was able to immunoprecipitate CBP/p300 
acetyltransferase in untreated hepatocytes, while the TGFβ 
treatment early reduces this protein–protein interaction. 
Notably, the total amount of CBP/p300 was not affected by 
TGFβ treatment.
Overall, these findings indicate that the loss of physical 
interaction between of CBP/p300 and HNF1α, with consequent 
displacement of the acetyl-transferase activity from the 
regulatory regions of HNF1α target genes, represents the first 
step of TGFβ-induced HNF1α inactivation, contributing to 
the onset of EMT in hepatocytes.
TGFβ Induces PTMs of HNF1α Protein
Our previous report unveiled that TGFβ induces a modification 
of HNF4α phosphorylation profile responsible for protein 
functional inactivation (Cozzolino et al., 2013). Thus, in the 
attempt to further investigate on the mechanism responsible 
for the reduced interaction between HNF1α and CBP/p300, we 
analyzed the effect of TGFβ on HNF1α PTM profile. To this 
aim, we performed a two-dimensional gel electrophoresis with 
nuclear extracts from untreated and TGFβ-treated hepatocytes 
(3  h), ectopically expressing HNF1αMyc, followed by Western 
blot with a Myc-Tag-specific antibody. As shown in Figure 4C, 
TGFβ strongly affects the PTM pattern on HNF1α protein. In 
particular, new specific “spot trains,” compatible with multiple 
phosphorylation/dephosphorylation events, and probably 
revealing intermediate isoforms, were observed. Some of 
these modifications might account for the observed altered 
interaction of HNF1α with CBP/p300, even if we cannot 
exclude the presence of additional PTMs nor the involvement 
of additional mechanisms (e.g., modulation of cofactors 
induced by TGFβ) that can affect protein complex formation.
DISCUSSION
The major contribution of the present work has been to unveil 
a novel mechanism by which TGFβ early affects the trans-
activating function of the MET master gene HNF1α in triggering 
EMT process in hepatocytes.
The pleiotropic TGFβ cytokine has emerged as a pivotal 
player in hepatocarcinogenesis, taking part in the interplay 
between microenvironment and liver cells from initial liver 
injury and inflammation through fibro/cirrhosis to tumor 
onset, growth, and metastasization (Amicone and Marchetti, 
2018). In particular, at late stage of hepatocarcinogenesis, the 
unbalanced level of the cytokine in the tumor niche can drive 
transformed hepatocytes towards an EMT and, ultimately, to 
the acquisition of migratory and invasive properties (Fabregat 
et al., 2016). Accordingly, in HCC patients, it has been 
observed that the constitutive activation of TGFβ signaling 
contributes to tumor progression and is associated with a 
poor prognosis (Lee et al., 2012).
One of the key events during the progression of hepatocellular 
carcinoma is the loss of expression of master genes of epithelial/
hepatocyte differentiation, such as HNF4α and HNF1α, that play 
a pivotal role in the restraint of inflammation, fibrosis, and EMT 
(Yue et al., 2010; Hatziapostolou et al., 2011; Pelletier et al., 2011; 
Santangelo et al., 2011; Qian et al., 2015).
Our previous data demonstrated the ability of TGFβ signaling 
to downregulate HNF4α and HNF1α gene expression through the 
Snail-mediated transcriptional repression and, even before the 
transcriptional control, to affect the HNF4α activity by inhibiting 
its DNA binding capacity (Cozzolino et al., 2013). Results of this 
work demonstrated that TGFβ is able to early inactivate also 
HNF1α, acting at posttranslational level.
These observations suggest that the use of HNF1α, 
elsewhere proposed as therapeutic tool in the control of liver 
fibrosis and tumor development, could be ineffective in an 
in vivo TGFβ-containing microenvironment. On the other 
hand, the knowledge of the molecular basis of the TGFβ-
induced HNF1α inactivation results is necessary to design new 
therapeutic approaches based on the use of molecules resistant 
to the inactivating effect of the cytokine.
Here, we demonstrated that (i) the functional inactivation of 
HNF1α protein by TGFβ precedes the effects of the transcriptional 
downregulation of its gene, (ii) TGFβ does not interfere with the 
HNF1α DNA-binding capability or its subcellular localization but 
induces a local reduction of chromatin acetylation at the HNF1α 
binding sites within target gene promoters, and (iii) TGFβ 
interferes with the recruitment of CBP/p300 acetyltransferases 
by HNF1α on target gene promoters, which could be due to a 
change of PTMs on HNF1α protein.
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To accomplish its functions on specific targets, 
HNF1α often cooperates with coactivators or corepressor, 
including CBP/p300 acetyltransferases that play an 
important role in positively regulating transcription of 
hepatocyte-specific genes.
In general, p300 and CBP seem to act as transcriptional 
coactivators by bridging the activators to the basal 
transcriptional machinery and, through their histone 
acetyltransferase (HAT) activity, by modifying chromatin 
structure to a locally open and transcriptionally active 
configuration (Chan and La Thangue, 2001).
HNF1α/CBP and HNF1α/p300 physical interactions 
have been previously reported (Soutoglou et al., 2000; Ban 
et al., 2002; Dohda et al., 2004). Furthermore, both CBP and 
p300 were found to interact with HNF1α on the Albumin 
promoter and to cooperatively enhance its expression in 
primary hepatocytes (Dohda et al., 2004). The ability of HNF1α 
to direct nucleosome hyper-acetylation to target genes is 
FIGURE 4 | (A) Analysis of CBP/p300 DNA binding activity after TGFβ treatment. qPCR analysis of chromatin immunoprecipitated with anti-CBP/p300 antibody 
from hepatocytes untreated or treated with TGFβ (for 5 h) was performed. HNF1α consensus regions embedded in the indicated target gene promoters were 
analyzed. A HNF1α nonbound region of Neurogenin 1 promoter was utilized as negative control. Data are normalized to total chromatin input and background 
(control immunoprecipitation with IgG) and expressed as % input. Mean ± SEM of qPCR data obtained in triplicate from three independent experiments are 
reported. (B) In vivo coimmunoprecipitation of HNF1α and CBP/p300 in hepatocytes untreated or treated with TGFβ (for 5 h). Cells were lysed, immunoprecipitated 
with anti-HNF1α antibody, and then analyzed by Western blotting with the indicated antibodies. As control, the immunoprecipitation with normal goat IgG was 
performed. TCE, total cell extracts. Densitometric analysis of WB data from three independent experiments is shown. (C) Analysis of HNF1α protein PTMs following 
TGFβ treatment. Nuclear extracts from control hepatocytes (upper panel) and HNF1αMyc-overexpressing hepatocytes treated for 3 h with TGFβ (lower panel) or left 
untreated (middle panel). Samples were separated by two-dimensional gel electrophoresis followed by Western blotting with anti-Myc-Tag antibody. HNF1α-specific 
spots are indicated by the arrow. The appearance of multiple spots in TGFβ-treated hepatocytes can be observed. **p <0.05, **p<0.01.
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fundamental for its transcriptional activity. A study carried 
out with hnf1α−/− mice models demonstrated that the organ-
specific induction of different targets is strongly dependent 
on nucleosome acetylation (Parrizas et al., 2001). Our results 
confirmed the pivotal role of CBP/p300 as transcriptional 
coactivator of HNF1α and indicated the impairment of the 
interaction between the two proteins as an effective and early 
mechanism utilized by TGFβ to neutralize the HNF1α activity 
in the first phase of EMT process.
It has been described for some transcriptional factors 
known to recruit CBP and p300 on target genes the role of 
specific PTMs in mediating the physical protein–protein 
interaction (Chrivia et al., 1993; Wang et al., 2013). Previous 
proteomic studies on liver cells highlighted the presence of 
PTMs on HNF1α protein. However, at present, there are only 
a few studies showing the role of these PTMs on its functional 
activity (Lim et al., 2002; Zhao et al., 2014; Kaci et al., 2018). 
Data obtained by 2-DE gel electrophoresis analysis suggest 
that the regulation of HNF1α-CBP/p300 interaction by 
TGFβ could include HNF1α posttranslational modifications. 
Further proteomic analysis will allow the identification of 
residues involved and their functional significance. We cannot 
exclude, in fact, that additional mechanisms could contribute 
to the impairment of HNF1α activity by TGFβ.
The early neutralization of HNF1α activity has great 
relevance in the induction of EMT process in hepatocyte. 
In differentiated hepatocyte, in fact, it has been shown that 
HNF1α, as well as HNF4α, stably inhibits the expression 
of the EMT master gene Snail and, consequently, the 
mesenchymal program and that this control is mandatory for 
the maintenance of the differentiated phenotype (Santangelo 
et al., 2011; Battistelli et al., 2018). The late events involved 
in the TGFβ-dependent downregulation of both HNF1α and 
HNF4α have been previously characterized. Our previous 
works, indeed, described their transcriptional downregulation 
by TGFβ through the recruitment of Snail to HNF1α and 
HNF4α promoters with subsequent chromatin remodeling 
and transcriptional repression (Santangelo et al., 2011; 
Battistelli et al., 2017).
Thus, the early functional inhibition of HNF1α and HNF4α 
by TGFβ (even if through different mechanisms, as shown in 
Figure 5) could represent the first mechanism through which 
the expression of Snail and the mesenchymal program are 
released, and the EMT process is triggered.
In conclusion, the data presented here shed light on an 
early mechanism inhibiting HNF1α function during the first 
step of EMT process in hepatocytes and, consequently, unveils 
a potential limitation of the use of HNF1α as therapeutic 
tool for anti-EMT and antifibrosis molecular therapies in 
an in vivo TGFβ-containing microenvironment. Further 
characterization of the change in the HNF1α PTM profile, 
induced by TGFβ, could allow the design of new therapeutic 
FIGURE 5 | Proposed mechanisms of HNF1α and HNF4α inactivation by TGFβ in EMT. In hepatocytes, TGFβ induces the impairment of HNF4α DNA binding 
ability through the loss of activating phosphorylations of the protein and the impairment of HNF1α functional activity through the displacement of CBP/p300 
acetyltransferases from target gene promoters, possibly mediated by change in PTM profile.
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approaches (i.e., mutant molecules resistant to the induction 
of these modifications) aimed to override the inactivating 
effect of the cytokine.
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